Margaret S. Lee
Geen lopende functies
Profiel
Margaret S.
Lee worked as VP-Research & Translational Development at Karyopharm Therapeutics, Inc. and as Vice President-Research & Translational Medicine at Zalicus, Inc. She holds a doctorate degree from Sackler School of Graduate Biomedical Sciences.
Eerdere bekende functies van Margaret S. Lee
| Bedrijven | Functie | Einde |
|---|---|---|
Zalicus, Inc.
 Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Hoofd Techniek/Wetenschap/O&O | - |
| KARYOPHARM THERAPEUTICS INC. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Margaret S. Lee
| Sackler School of Graduate Biomedical Sciences | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Zalicus, Inc.
Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |
